Tobias Granberg

Tobias Granberg

Adjunct Professor | Docent
Visiting address: , Stockholm
Postal address: K8 Klinisk neurovetenskap, K8 Neuro Granberg, 171 77 Stockholm
Part of:

About me

  • I am an Adjunct Professor of Neuroradiology and Research Group Leader for Neuroradiology focusing on Neurodegenerative and Neuroinflammatory disorders and also serve as the Scientific Director of KI MRI Center Core Facility. 

    After graduating from medical school at Karolinska Institutet (KI) in 2012, I undertook a two-year clinical internship at Västerås Regional Hospital. Thereafter, I completed my residency in Radiology at Karolinska University Hospital between 2014-2019. This was followed by a fellowship in Neuroradiology 2019-2022.  

    Academically, I started conducting MRI research in 2009, writing my medical thesis on MRI detection of Cerebral microbleeds in Alzheimer's disease using Susceptibility-Weighted Imaging. My PhD focused on Neuroradiological aspects of Multiple Sclerosis (MS), which I defended in 2015. I thereafter conducted a post-doctoral research fellowship at Massachusetts General Hospital and Harvard Medical School. My post-doctoral work focused on MS diagnostics using a combination of 7 Tesla MRI, 11C-PBR28 (2nd generation TSPO marker for microglia) PET-MR and Human Connectom Scanner with 300 mT/m gradients (compared to typical 40-80 mT/m clinical gradients). I also continued developing and validating myelin quantification techniques.  

    Upon my return to Karolinska Institutet, I established our research group at the Clinical Neuroscience department at KI, where we continue to focus on Quantitative imaging techniques and their applications to improve the diagnostics, prognostics and treatment evaluation in pathologies such as MS, dementia disorders, movement disorders and ALS.  

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2024 - 31 December 2027
    Background: Amyotrophic lateral sclerosis (ALS) is a fatal disorder with heterogeneous clinical expression. While overt morphological findings are often preceded by hypometabolism in ALS, FDG-PET is sparsely used in routine clinical practice due to costs and a somewhat uncertain diagnostic/predictive value. Meanwhile, GlucoCEST MRI is a novel radiation-free method for imaging metabolism that has yet to be applied in ALS.Aim: To evaluate the feasibility and accuracy of GlucoCEST MRI for assessing brain metabolism in ALS and study its diagnostic and predictive value.Methods: A prospective study with 120 persons with ALS and 60 matched controls will be conducted at Karolinska University Hospital using a second-generation clinical 7 Tesla MRI scanner. GlucoCEST will be processed and analyzed using advanced post-processing techniques and compared to the gold-standard, FDG-PET imaging, in patients. Patients will be longitudinally followed comprehensively over up to 4 years.Significance: GlucoCEST can integrate metabolic and structural information from a single scan to detect early neurodegeneration at a lower cost and with less patient risk and -burden than FDG-PET. As a radiation-free technique, the method is especially suitable for precision medicine approaches since it can track disease progression over time to advance our understanding of neurodegenerative disease processes and monitor the efficacy of emerging disease-modifying treatments in clinical trials.
  • Swedish Research Council
    1 December 2023 - 30 November 2027
    This translational project explores mechanisms and pathophysiology, prevention and outcomes related to long-term neurocognitive decline and risk for dementia after major surgery. The ultimate goal is to provide novel prognostic and therapeutic strategies and patient-centered guidelines for safer perioperative care. We hypothesize that adverse immune response signatures to surgical trauma with impaired periphery-to-brain communication leads to unresolved systemic and neuroinflammation with risk for neurocognitive decline and dementia. Using comprehensive clinical and experimental platforms in man, animals and cells, we will in standardized surgical cohorts in Part A define a longitudinal in-depth immunological, transcriptional, and soluble atlas with a periphery-to-brain axis coupled to hard adverse brain outcomes related to neuroinflammation, neurodegeneration and risk for dementia. Key findings from this effort will in Part B be mechanistically explored in established animal models and in vitro systems to provide in-depth knowledge on targets for prognostic and possibly therapeutic strategies. Information from preclinical and clinical investigations (Part A-B) on precision-based immune signatures will be prospectively validated in broader surgical populations to search at-risk patients (part C). This knowledge will ultimately serve as base for novel perioperative guidelines and therapeutic strategies to prevent neurocognitive decline or dementia after surgery.
  • Swedish Research Council
    1 January 2023 - 31 December 2025
  • Swedish Heart-Lung Foundation
    1 January 2021 - 31 December 2021
  • Swedish Research Council
    1 January 2018 - 31 December 2020

Employments

  • Adjunct Professor, Department of Clinical Neuroscience, Karolinska Institutet, 2025-2029
  • Senior Research Specialist, Department of Clinical Neuroscience, Karolinska Institutet, 2020-2025

Degrees and Education

  • Docent, Karolinska Institutet, 2021
  • Degree Of Doctor Of Philosophy, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2015
  • University Medical Degree, Karolinska Institutet, 2012

Supervision

News from KI

Events from KI